| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
|
N Engl J Med
|
2001
|
20.20
|
|
2
|
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
|
N Engl J Med
|
2006
|
18.25
|
|
3
|
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
|
Lancet
|
1996
|
16.32
|
|
4
|
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
|
Lancet
|
2001
|
8.54
|
|
5
|
Genetic determinants of response to clopidogrel and cardiovascular events.
|
N Engl J Med
|
2008
|
8.39
|
|
6
|
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
|
JAMA
|
2009
|
7.78
|
|
7
|
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
|
N Engl J Med
|
2005
|
6.39
|
|
8
|
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
|
CMAJ
|
2009
|
6.21
|
|
9
|
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
|
J Am Coll Cardiol
|
2008
|
5.77
|
|
10
|
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
|
N Engl J Med
|
1996
|
2.37
|
|
11
|
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2009
|
2.06
|
|
12
|
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
|
Gastroenterology
|
2009
|
1.80
|
|
13
|
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
|
Gastroenterology
|
2010
|
1.62
|
|
14
|
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.
|
Gastroenterology
|
1997
|
1.59
|
|
15
|
Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release.
|
Proc Natl Acad Sci U S A
|
2001
|
1.39
|
|
16
|
Clopidogrel: a review of its mechanism of action.
|
Platelets
|
1998
|
1.05
|
|
17
|
Proton pump inhibitor and clopidogrel interaction: fact or fiction?
|
Am J Gastroenterol
|
2009
|
0.97
|
|
18
|
Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study.
|
Scand J Gastroenterol
|
2000
|
0.92
|
|
19
|
Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers.
|
Gastroenterology
|
1999
|
0.89
|
|
20
|
High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection.
|
Eur J Clin Invest
|
2007
|
0.88
|
|
21
|
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
|
Aliment Pharmacol Ther
|
2003
|
0.87
|
|
22
|
P2Y receptor antagonists in thrombosis.
|
Curr Opin Investig Drugs
|
2005
|
0.84
|
|
23
|
Risk of combining PPIs with thienopyridines: fact or fiction?
|
Lancet
|
2009
|
0.77
|